US Senate bill aimed at streamlining combination product regulation
This article was originally published in Clinica
A new US Senate bill, the Combination Product Regulatory Fairness Act of 2015, is intended to streamline device/drug combination registrations at the FDA by letting the agency rely on prior PMAs and approved drug findings to support new product approvals, among other reforms.
You may also be interested in...
The US Senate overwhelmingly approved a bill on 16 January to implement the US-Mexico-Canada agreement, which includes a new chapter on the handling of medical devices supported by the medtech industry.
The Agency for Healthcare Research and Quality (AHRQ) is conducting a review on treatments for acute pain and is asking device manufacturers and other organizations to supply it with studies on nonpharmacological therapies to control pain, including transcutaneous electrical nerve stimulation, ultrasound, heat- and cold-producing devices, and acupuncture.
Brad Smith, the former CEO of Aspire Health, a home-based palliative-care company, was appointed director of the Center for Medicare and Medicaid Innovation (CMMI) at the US Medicare agency CMS.